Abstract Number: 2459 • ACR Convergence 2023
Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals
Background/Purpose: Reporting of race and ethnicity as social constructs is critical to highlight equity and diversity of study participants, with the knowledge that socio-economic factors…Abstract Number: 2552 • ACR Convergence 2023
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Background/Purpose: Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells. However, this is typically regarded as nonspecific "scar reaction" rather than active…Abstract Number: 0097 • ACR Convergence 2023
Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: APS ACTION Registry aims to study the course of disease in antiphospholipid antibody (aPL)-positive patients. Although transient ischemic attack (TIA) can develop in aPL-positive…Abstract Number: 0182 • ACR Convergence 2023
Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus
Background/Purpose: Racial disparities in outcomes of pediatric SLE (pSLE) have persisted over time. This may be mediated by structural racism, which segregates children belonging to…Abstract Number: 0461 • ACR Convergence 2023
Self-esteem as a Determinant of Sexual Function in SLE Patients
Background/Purpose: Rheumatic diseases, and specifically SLE, present with greater sexual dysfunction than other chronic diseases. Sexual dysfunction (SxD) is multifactorial and comprises disease-related factors, psychological…Abstract Number: 0553 • ACR Convergence 2023
Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 2-3-fold increased risk of cardiovascular events. A major risk factor for this is hypertension. We previously…Abstract Number: 0570 • ACR Convergence 2023
BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations
Background/Purpose: Autoantibodies and auto reactive B cells participate on the pathogenesis of systemic lupus erythematosus (SLE), affecting various organs and tissues, including the nervous system,…Abstract Number: 0588 • ACR Convergence 2023
Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry
Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…Abstract Number: 0828 • ACR Convergence 2023
Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire
Background/Purpose: Cutaneous lupus erythematosus (CLE) symptoms often require patient-reported outcome measures (PROMs) to monitor disease progression. The CLE quality of life (CLEQoL) instrument was devised…Abstract Number: 0901 • ACR Convergence 2023
Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus
Background/Purpose: Atherosclerosis and vascular inflammation are a cause of morbidity and mortality in systemic lupus erythematosus (SLE). Vascular NETosis is a driver of atherosclerosis and…Abstract Number: 0918 • ACR Convergence 2023
Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…Abstract Number: 1091 • ACR Convergence 2023
Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
Background/Purpose: Quality of care (QoC) in SLE patients has been studied by Schmajuk et al. (Arthritis Care Res2022), who developed six quality measures assessing blood…Abstract Number: 1242 • ACR Convergence 2023
Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Executive functions (EFs) are a set of cognitive skills that enable successful problem solving and goal-directed behavior. EFs are predictive of academic success, mental…Abstract Number: 1444 • ACR Convergence 2023
Identifying Determinants of Favourable and Poor Physical Function in Systemic Lupus Erythematosus: Results from an International Collaborative Study
Background/Purpose: Systemic lupus erythematosus (SLE) can result in impaired daily physical function through various mechanisms including active disease, chronic damage, and mental health symptoms that…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 181
- Next Page »
